Testicular cancer is treated primarily through surgery to remove the affected testicle, followed by additional therapy based on the cancer type and stage. It is one of the most curable cancers: the five-year survival rate is 99% for localized disease, 96% when it has spread to nearby lymph nodes, and 72% for distant spread.
Surgery Comes First
Nearly every case of testicular cancer begins with a procedure called a radical orchiectomy. The surgeon makes an incision of about 5 to 10 centimeters in the groin, not the scrotum. The reason for this approach is that the spermatic cord (the bundle of vessels and nerves leading to the testicle) needs to be removed as high up toward the body as possible to prevent cancer cells from spreading along that pathway. Through the groin incision, the surgeon frees the testicle and cord from the inguinal canal and removes them together.
The surgery can be done under general or local anesthesia, and most people go home the same day. Expect bruising, swelling, and tenderness in the scrotum for two to four weeks afterward. The removed testicle is sent to a pathologist, and what happens next depends almost entirely on what they find under the microscope.
Seminoma vs. Non-Seminoma: Why It Matters
Testicular cancers are divided into two broad categories: seminomas and non-seminomas. This distinction drives every treatment decision that follows surgery, because the two types respond differently to therapy.
Seminomas are more sensitive to both radiation and chemotherapy and less likely to spread to distant sites. Non-seminomas can contain a tissue type called teratoma, which resists chemotherapy and often requires additional surgery to remove. Because of this, surgery plays a larger role in managing non-seminomas than seminomas. If a tumor looks like a seminoma under the microscope but a blood marker called AFP is elevated, it gets treated as a non-seminoma, since pure seminomas never produce AFP.
Stage I: When Cancer Hasn’t Spread
Stage I means the cancer is confined to the testicle. At this point, cure rates approach 100% for seminomas regardless of whether any additional treatment is given after orchiectomy. For non-seminomas, removing the testicle alone cures about 70% of patients, but the remaining 30% will eventually relapse and need further treatment.
After orchiectomy, you and your doctor will choose among three paths:
- Surveillance: No immediate treatment. Instead, you follow a structured schedule of blood tests and CT scans to catch any recurrence early. For stage I seminoma on surveillance, imaging is most frequent in the first year (CT scans at 3, 6, and 12 months) and gradually spaces out over five years.
- Radiation (seminoma only): A targeted course of radiation to the lymph nodes along the aorta, delivered at a dose of 20 Gy over about two weeks (ten daily sessions). This option has largely fallen out of favor compared to surveillance or chemotherapy, but remains effective.
- Adjuvant chemotherapy: One or two cycles of chemotherapy to reduce the risk of relapse. For non-seminomas, this typically involves a combination of bleomycin, etoposide, and cisplatin (called BEP).
Another option for non-seminomas is a retroperitoneal lymph node dissection, or RPLND, which removes lymph nodes in the back of the abdomen where testicular cancer tends to spread first. This serves double duty: it stages the cancer precisely and removes any nodes that might already harbor microscopic disease.
Stage II and III: When Cancer Has Spread
When testicular cancer reaches the lymph nodes or distant organs, treatment intensifies but cure rates remain high.
For seminomas with modest lymph node spread (non-bulky stage II), radiation therapy alone cures 90% to 95% of cases. When the involved nodes are larger (5 cm or more), chemotherapy with cisplatin-based combinations becomes the standard approach.
For non-seminomas with significant lymph node involvement or distant spread, the backbone of treatment is systemic chemotherapy. The standard regimen for patients with a favorable prognosis is three cycles of BEP. An alternative of four cycles of etoposide and cisplatin (EP) has been shown to be equally effective for that group.
One key difference between the two cancer types shows up after chemotherapy ends. In non-seminomas, any masses remaining on imaging after chemo need to be surgically removed whenever possible, because 10% to 15% of these masses contain viable cancer and 40% to 50% contain teratoma that won’t respond to further chemotherapy. In seminomas, leftover masses on scans are common and are typically just monitored unless they grow or a biopsy shows active cancer.
Lymph Node Surgery and Nerve Sparing
RPLND is a significant operation. The lymph nodes being removed sit deep in the abdomen, right next to the nerves that control ejaculation. Without careful technique, damage to these nerves can cause a condition where semen travels backward into the bladder instead of being expelled during orgasm, effectively causing infertility through that route.
Modern nerve-sparing techniques have dramatically reduced this risk. When performed as a primary procedure (not after chemotherapy), the rate of inability to ejaculate is 5% to 10%. Post-chemotherapy RPLND is technically harder because chemotherapy can make tissues scar and stick together, but experienced surgeons at high-volume centers still achieve good nerve-preservation outcomes.
Blood Markers Track Your Progress
Three blood proteins help doctors monitor how well treatment is working and whether cancer returns. AFP (alpha-fetoprotein) has a half-life of 5 to 7 days, meaning it should drop by half roughly every week after the cancer is removed. HCG (human chorionic gonadotropin) clears faster, with a half-life of 24 to 36 hours. LDH (lactate dehydrogenase) reflects overall tumor burden and has a 24-hour half-life.
If these markers don’t fall at the expected rate after surgery or chemotherapy, it signals that cancer cells are still active somewhere. During surveillance, a rising marker can detect a relapse months before it would show up on a scan. For stage I seminoma patients on surveillance, markers are typically checked every two months in the first year, every three months in the second year, and less frequently after that through year five.
Fertility Preservation Before Treatment
Chemotherapy, radiation, and lymph node surgery can all affect fertility. Chemotherapy damages sperm cells and can temporarily or permanently reduce sperm production. Radiation to the abdomen can scatter to the remaining testicle. Even the orchiectomy itself removes half of your sperm-producing capacity.
If you want biological children in the future, sperm banking should happen before treatment begins. This conversation needs to take place early, ideally before the orchiectomy or, at the very latest, before starting chemotherapy or radiation. Banked sperm can be stored indefinitely and used later for assisted reproduction.
During and after chemotherapy, damaged sperm can cause birth defects, and some chemotherapy drugs can even be passed to a partner through semen. Most oncologists recommend waiting several months or longer after completing treatment before attempting conception naturally.
What Long-Term Follow-Up Looks Like
Even after successful treatment, testicular cancer requires years of monitoring. The surveillance schedule varies by stage and treatment received, but the general pattern is intensive early on and tapering over time. For a stage I seminoma patient who chose surveillance only, a typical schedule involves CT scans three times in the first year, then every 6 to 12 months for two more years, then annually or every other year through year five. Patients who received adjuvant chemotherapy or radiation generally need fewer scans because their relapse risk is already reduced.
Physical exams and blood marker checks continue alongside imaging. The remaining testicle carries a small but real risk of developing a new cancer, so self-exams remain important long after treatment ends. Most relapses occur within the first two years, which is why monitoring is most aggressive during that window.